News

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter

Pharmaceutical Technology\'s In the Lab eNewsletter-03-06-2019
Volume14
Issue 3

Novartis, AbCellera in Antibody Discovery Pact

The multi-year agreement will give Novartis access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.

On Feb. 14, 2019, AbCellera Biologics, an antibody discovery company, announced a multi-target and multi-year collaboration with Novartis in which AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by Novartis.

Under the agreement, AbCellera is eligible to receive technology access, research funding, downstream milestone payments, and royalties on net sales of products.

“AbCellera continues to build its reputation as a high-powered innovation shop and the premier provider for therapeutic antibody discovery from natural immune responses. This partnership with Novartis marks an important evolution of our partnering strategy, expanding from target-based collaborations to deal structures that encourage long-term relationships and provide extended technology access to select partners,” said Carl Hansen, president and CEO of AbCellera, in a company press release.

Over the past three years, AbCellera has completed more than thirty antibody discovery programs, including deals with seven global pharmaceutical companies and top-tier public and venture-backed biotech companies. Applying best-in-class technology and custom innovation to each project, AbCellera enables programs for any target class, including difficult multi-pass membrane proteins, and provides a competitive advantage through diversity, speed, and quality.

Source: AbCellera Biologics

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content